JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Endocrinology (1994) 141, 555-563       DOI: 10.1677/joe.0.1410555
© 1994 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by James, S Y
Right arrow Articles by Colston, K W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by James, S Y
Right arrow Articles by Colston, K W

Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells

 S Y James, A G Mackay, L Binderup and K W Colston

The anti-proliferative effects of the novel vitamin D analogue, EB1089, were assessed in the hormone-dependent breast cancer cell line, MCF-7, in vitro. In the present study, EB1089 was shown to be at least an order of magnitude more potent at inhibiting MCF-7 cell proliferation than the native hormone, l{alpha},25-dihydroxyvitamin D3 (1,25(OH)2D3). Treatment of MCF-7 cell cultures with combinations of oestradiol and EB1089 ranging from 5 x 10–11 M to 5 x 10–9 M revealed the ability of EB1089 to suppress the mitogenic effects of oestradiol in these cells dose-dependently, as determined by [3H]thymidine incorporation and cell counts. EB1089 also exhibited a significant time- and dose-dependent decrease in MCF-7 oestrogen receptor (ER) concentration, as assessed by ligand binding assay. A fourfold reduction of ER levels by 5 x 10–9 M EB1089 relative to control ER levels was observed, whilst 5 x 10–9 M 1,25(OH)2D3 produced a significant but less dramatic decrease in ER levels. In addition, reduction of ER protein in EB1089-treated cell cultures was also demonstrated using an oestrogen receptor enzyme immunoassay.

The interaction of EB1089 and anti-oestrogens on the oestradiol-stimulated growth of MCF-7 cells was investigated. The treatment of cell cultures with 5 x 10–10 M EB1089 in combination with the pure anti-oestrogen, ICI 182,780 (5 x 10–8 M), and in the presence of between 5 x 10–10 M and 5 x 10–9 M oestradiol, produced an augmented inhibition of MCF-7 cell proliferation compared with the actions of either compound alone.

This study demonstrates that EB1089 is a potent anti-proliferative agent of breast cancer cells in vitro, and that part of its mechanism to inhibit cell growth may involve the modulation of ER expression, such that the responsiveness of cells to the growth-stimulatory effects of oestradiol is diminished. This new vitamin D analogue has potential in the treatment of breast cancer.

Journal of Endocrinology (1994) 141, 555–563




This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Abbas, J. Linseisen, T. Slanger, S. Kropp, E. J. Mutschelknauss, D. Flesch-Janys, and J. Chang-Claude
The Gc2 Allele of the Vitamin D Binding Protein Is Associated with a Decreased Postmenopausal Breast Cancer Risk, Independent of the Vitamin D Status
Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1339 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. L. McCullough, C. Rodriguez, W. R. Diver, H. S. Feigelson, V. L. Stevens, M. J. Thun, and E. E. Calle
Dairy, Calcium, and Vitamin D Intake and Postmenopausal Breast Cancer Risk in the Cancer Prevention Study II Nutrition Cohort
Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2898 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Li, C. Li, X. Zhao, X. Zhang, S. V. Nicosia, and W. Bai
p27Kip1 Stabilization and G1 Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through Down-regulation of Cyclin E/Cyclin-dependent Kinase 2 and Skp1-Cullin-F-box Protein/Skp2 Ubiquitin Ligase
J. Biol. Chem., June 11, 2004; 279(24): 25260 - 25267.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Jiang, P. Li, A. J. Fornace Jr., S. V. Nicosia, and W. Bai
G2/M Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through the Induction of GADD45 via an Exonic Enhancer
J. Biol. Chem., November 28, 2003; 278(48): 48030 - 48040.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Sundaram, A. Sea, S. Feldman, R. Strawbridge, P. J. Hoopes, E. Demidenko, L. Binderup, and D. A. Gewirtz
The Combination of a Potent Vitamin D3 Analog, EB 1089, with Ionizing Radiation Reduces Tumor Growth and Induces Apoptosis of MCF-7 Breast Tumor Xenografts in Nude Mice
Clin. Cancer Res., June 1, 2003; 9(6): 2350 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Pepper, A. Thomas, T. Hoy, D. Milligan, P. Bentley, and C. Fegan
The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro
Blood, April 1, 2003; 101(7): 2454 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
K. El Abdaimi, V. Papavasiliou, D. Goltzman, and R. Kremer
Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes
Am J Physiol Cell Physiol, October 1, 2000; 279(4): C1230 - C1238.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. El Abdaimi, N. Dion, V. Papavasiliou, P.-E. Cardinal, L. Binderup, D. Goltzman, L.-G. Ste-Marie, and R. Kremer
The Vitamin D Analogue EB 1089 Prevents Skeletal Metastasis and Prolongs Survival Time in Nude Mice Transplanted with Human Breast Cancer Cells
Cancer Res., August 1, 2000; 60(16): 4412 - 4418.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. Swami, A. V. Krishnan, and D. Feldman
1{{alpha}},25-Dihydroxyvitamin D3 Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells
Clin. Cancer Res., August 1, 2000; 6(8): 3371 - 3379.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
A.-C. Lundin, P. Soderkvist, B. Eriksson, M. Bergman-Jungestrom, and S. Wingren
Association of Breast Cancer Progression with a Vitamin D Receptor Gene Polymorphism
Cancer Res., May 1, 1999; 59(10): 2332 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
C. Agarwal, A. Lambert, R. A.S. Chandraratna, E. A. Rorke, and R. L. Eckert
Vitamin D Regulates Human Ectocervical Epithelial Cell Proliferation and Insulin-Like Growth Factor-Binding Protein-3 Level
Biol Reprod, March 1, 1999; 60(3): 567 - 572.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
A. Ravid, D. Rocker, A. Machlenkin, C. Rotem, A. Hochman, G. Kessler-Icekson, U. A. Liberman, and R. Koren
1,25-Dihydroxyvitamin D3 Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage
Cancer Res., February 1, 1999; 59(4): 862 - 867.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. VanWeelden, L. Flanagan, L. Binderup, M. Tenniswood, and J. Welsh
Apoptotic Regression of MCF-7 Xenografts in Nude Mice Treated with the Vitamin D3 Analog, EB1089
Endocrinology, April 1, 1998; 139(4): 2102 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. J. Narvaez and J. Welsh
Differential Effects of 1,25-Dihydroxyvitamin D3 and Tetradecanoylphorbol Acetate on Cell Cycle and Apoptosis of MCF-7 Cells and a Vitamin D3-Resistant Variant
Endocrinology, November 1, 1997; 138(11): 4690 - 4698.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Society for Endocrinology.